newsfilter
← Latest News
GlobeNewswire·

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

— First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to MASH — — Phase 3 SYNCHRONY Real-World and Histology studies on track to